Paradoxically, at the lower drug combination dose examined (0.3 valsartan/1 mg/kg per day sacubitril: 24.4 ± 10.7, n = 5) there was a significant increase in atherosclerotic lesion surface area compared with vehicle, even though neither sacubitril nor valsartan at these doses influenced AngII-induced atherosclerosis when administered as individual agents (Fig. 4C; P < 0.05). The gene discussed is AGT; the disease is atherosclerosis.